Colorectal cancer is a leading cause of death in America, killing 50,000 people each year. But if it’s caught early, the survival rate after five years is 90% . Despite those favorable odds, only about four in 10 colorectal cancers are spotted at the early stage.
There are several reasons why more people aren't getting screened for this devastating cancer. Some aren't aware that regular testing can save their lives, many can't afford it, while others don't have access. Colonoscopies done at ten-year intervals and occult blood tests (FITS) performed annually or biannually are the two forms of screenings, but both have disadvantages.
Colonoscopies, while very precise, involve an unpleasant procedure and lengthy intestinal cleansing. Occult blood tests are more widely accepted, but they can only provide indirect evidence of disease and often only in later, bleeding stages. Advanced Screening Equals Early Detection To be effective, cancer screening has to be simple, readily available and affordable, which is where Mainz Biomed MYNZ comes in.
The molecular genetics diagnostic company specializing in the early detection of cancer is revolutionizing the colorectal cancer testing industry with ColoAlert , its flagship product. ColoAlert is an early detection screening that spots bleeding and non-bleeding tumors through tumor DNA analysis, offering what the company says is better early detection than fecal occult blood tests. That's important since almost all colorectal cancers deve.
